Identification of a New Chemotype of Anti-Obesity Compounds by Ensemble Screening

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Drug Discovery

Background:

• Rising global obesity rates necessitate safer, long-term anti-obesity medications.
• Current obesity drugs often have severe cardiovascular and neurological side effects, limiting their use.

Purpose of the Study:

• To discover novel anti-obesity agents with reduced toxicity using a virtual screening approach.
• To identify compounds that inhibit lipid accumulation without significant adverse effects.

Main Methods:

• Developed a virtual screening (VS) model using Bayesian classification and a 3D pharmacophore.
• Screened an in-house library of natural piper amide-like compounds for anti-obesity potential.
• Evaluated identified compounds for lipid accumulation inhibition and toxicity in vitro and in vivo.

Main Results:

• Identified six compounds across different classes exhibiting potent lipid accumulation inhibition and low toxicity.
• The most active compound, featuring an oxadiazole scaffold, demonstrated significant weight loss in diet-induced obese mice.
• This lead compound also ameliorated fatty liver conditions in the animal model.

Conclusions:

• The virtual screening approach successfully identified promising anti-obesity candidates with a favorable safety profile.
• The oxadiazole compound represents a potential therapeutic agent for managing obesity and related metabolic disorders like fatty liver disease.